Efficacy and Safety of Dalpiciclib in HR+/HER2- Advanced Breast Cancer: a Real-world Study

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY

To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Histologically confirmed advanced breast cancer

• Hormone receptor-positive and human epidermal growth factor receptor 2-negative

• ECOG 0-1

Locations
Other Locations
China
Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITING
Shanghai
Contact Information
Primary
Wenjin Yin
yinwenjin@renji.com
86(21)68385569
Time Frame
Start Date: 2024-05-03
Estimated Completion Date: 2028-12
Participants
Target number of participants: 103
Treatments
dalpiciclib
dalpiciclib oral day 1-21, every 28 days
Related Therapeutic Areas
Breast Cancer
Sponsors
Leads: RenJi Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)

A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)

Enrollment Status: Recruiting
Publish Date: October 03, 2025
Intervention Type: Biological
Study Phase: Phase 3

Pilot Study of Positive Affect Training for Endocrine Therapy Medication Adherence

Pilot Study of Positive Affect Training for Endocrine Therapy Medication Adherence

Enrollment Status: Recruiting
Publish Date: April 29, 2024
Intervention Type: Behavioral
Study Phase: Not Applicable

A Randomized, Open-Label, Phase III Trial Comparing Adjuvant Trastuzumab Plus Neratinib Versus Trastuzumab Plus Pertuzumab in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer With Residual Cancer Burden 0/I After Neoadjuvant Trastuzumab Plus Pertuzumab

A Randomized, Open-Label, Phase III Trial Comparing Adjuvant Trastuzumab Plus Neratinib Versus Trastuzumab Plus Pertuzumab in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer With Residual Cancer Burden 0/I After Neoadjuvant Trastuzumab Plus Pertuzumab

Enrollment Status: Recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Phase: Phase 3
View All